DG
ADAP

David Goel’s Adaptimmune Therapeutics ADAP Stock Holding History

David Goel’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37,681,515
Closed -$35.8M – 6
2024
Q3 		$35.8M Sell
37,681,515
-1,292,670
-3% -$1.47M 1.71% 6
2024
Q2 		$38M Hold
38,974,185
– – 0.29% 20
2024
Q1 		$61.6M Hold
38,974,185
– – 0.57% 15
2023
Q4 		$30.9M Hold
38,974,185
– – 0.32% 17
2023
Q3 		$30.4M Hold
38,974,185
– – 0.36% 17
2023
Q2 		$36.1M Hold
38,974,185
– – 0.42% 16
2023
Q1 		$42.5M Hold
38,974,185
– – 0.58% 15
2022
Q4 		$56.9M Hold
38,974,185
– – 1.09% 14
2022
Q3 		$41.9M Hold
38,974,185
– – 0.8% 19
2022
Q2 		$66.3M Hold
38,974,185
– – 1.5% 14
2022
Q1 		$80.3M Hold
38,974,185
– – 0.96% 21
2021
Q4 		$146M Hold
38,974,185
– – 1.63% 16
2021
Q3 		$201M Hold
38,974,185
– – 2.29% 17
2021
Q2 		$166M Hold
38,974,185
– – 1.81% 18
2021
Q1 		$207M Hold
38,974,185
– – 2.39% 16
2020
Q4 		$210M Hold
38,974,185
– – 2.27% 17
2020
Q3 		$311M Hold
38,974,185
– – 4.13% 10
2020
Q2 		$390M Buy
38,974,185
+4,545,455
+13% +$28.5M 6.08% 7
2020
Q1 		$93.6M Buy
34,428,730
+6,428,730
+23% +$21.3M 2.39% 15
2019
Q4 		$33.6M Hold
28,000,000
– – 0.72% 19
2019
Q3 		$42.3M Hold
28,000,000
– – 1.04% 16
2019
Q2 		$113M Hold
28,000,000
– – 2.08% 17
2019
Q1 		$120M Buy
28,000,000
+851,000
+3% +$3.96M 3.21% 12
2018
Q4 		$156M Buy
27,149,000
+6,786,989
+33% +$50.1M 5.17% 8
2018
Q3 		$276M Buy
20,362,011
+6,278,500
+45% +$65.8M 6.82% 5
2018
Q2 		$167M Buy
14,083,511
+201,500
+1% +$2.51M 4.75% 8
2018
Q1 		$156M Buy
13,882,011
+1,668,500
+14% +$14.6M 5.42% 8
2017
Q4 		$81.6M Buy
12,213,511
+170,000
+1% +$1.31M 2.91% 12
2017
Q3 		$98.6M Buy
12,043,511
+3,351,428
+39% +$20.9M 3.15% 13
2017
Q2 		$39M Buy
+8,692,083
New +$45.4M 1.33% 16

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Goel's ADAP Position: Q4 2024 in Review

David Goel sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 37,681,515 shares — an estimated $35.8M sold.

David Goel first reported a position in ADAP in Q2 2017 and held it in 30 quarters. The position peaked at $390M in Q2 2020. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • David Goel reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • David Goel sold 37,681,515 Adaptimmune Therapeutics shares in Q4 2024, an estimated $35.8M.
  • David Goel first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 30 quarters.
  • David Goel's Adaptimmune Therapeutics position peaked at $390M in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Matrix Capital Management Company's 13F filing for Q4 2024, filed 13 Feb 2025.